LLY   $831.92  4.32% Market Closed After Close 832.28 0.04%

Eli Lilly and Co
Last Events:

2023-08-09 Signal in Stochastic changed from bearish to bullish reversal. The stochastic indicator is in the lower part of the neutral territory and left the oversold territory. These factors indicate that perhaps the downside trend is coming to an end price will probably head north Last signal: main and signal line crossing.

2023-08-09 Signal in MACD changed from bearish reversal to bullish recovery. Oscillator MACD is in the positive territory it's lower than the signal line and grows. These factors mean that positive mood prevails, but this trend does not have a significant strength. Last signal: main and signal line crossing.

2023-08-09 Signal in RSI changed from bearish weakening to bullish. RSI indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: entrance to the overbought zone.

2023-08-09 Signal in EMA20 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-08-08 The hottest instrument.

2023-08-06 Signal in RSI changed from bearish to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-05 Signal in RSI changed from bullish recovery to bearish. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-05 Signal in EMA20 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.


Current temperature: 4.35
ST: 0, Cor:

50-50 Year Forecast
Low with % probability:
Target: 1011.20
High with % probability:
Analyst Recommendations:
Number of estimates 26
Target Price Mean 1002.82
Mean unverified/preliminary 1002.82 / 1002.82
Target Price Low / High 700.00 / 1250.00
Median / STD DEV 1005.00 / 124.92
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell None
macd None None None
stoch None None None
ma20 Sell Sell None
ma50 None None None
ma100 Sell Sell Sell
Candlestick PatternNov. 4, 2024 Gravestone - is formed when the opening and closing prices are at the lowest of the day. If it has a longer upper shadow it signals a bearish trend. When it appears at market top it is considered a reversal signal.
ISIN US5324571083
ceo Mr. David A. Ricks
Website https://www.lilly.com
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.